Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS	4	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS	5	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS	6	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS	7	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	8	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS	9	MAR 22	EMBASE is now updated on a daily basis
NEWS	10	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS	11	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS	12	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS	13	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS	14	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS	15	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS	16	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS	17	MAY 11	KOREAPAT updates resume
NEWS	18	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	19	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS	20	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS	21	JUN 02	The first reclassification of IPC codes now complete in INPADOC

NEWS EXPRESS JUNE 16 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 23 MAY 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:10:04 ON 19 JUN 2006

```
=> file pctfull
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'PCTFULL' ENTERED AT 16:10:19 ON 19 JUN 2006
COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED:         13 JUN 2006      <20060613/UP>
MOST RECENT UPDATE WEEK:       200623        <200623/EW>
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOW AVAILABLE IN THIS FILE.
    SEE
    http://www.stn-international.de/stndatabases/details/ipc-reform.html >>>

>>> FOR CHANGES IN PCTFULL PLEASE SEE HELP CHANGE
    (last updated April 10, 2006) <<<

=> s WO0071135/pn
L1            0 WO0071135/PN
                (WO71135/PN)

=> s WO 0071135/pn
L2            0 WO 0071135/PN
                (WO71135/PN)

=> s WO200071135/pn
L3            1 WO200071135/PN
                (WO2000071135/PN)

=> s enhance? or synerg? or additi?
        279226 ENHANCE?
         36077 SYNERG?
        711063 ADDITI?
L4      734288 ENHANCE? OR SYNERG? OR ADDITI?

=> s l4 and l3
L5            1 L4 AND L3

=> d ibib kwic

L5     ANSWER 1 OF 1     PCTFULL   COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER:        2000071135 PCTFULL  ED 20020515
TITLE (ENGLISH):         ANTI-TUMOR COMPRISING BOROPROLINE COMPOUNDS
TITLE (FRENCH):          AGENTS ANTI-TUMORALES CONTENANT DES COMPOSES DE
                         BOROPROLINE
INVENTOR(S):             WALLNER, Barbara, P.;
                         MILLER, Glenn
PATENT ASSIGNEE(S):      POINT THERAPEUTICS, INC.
LANGUAGE OF PUBL.:       English
DOCUMENT TYPE:           Patent
PATENT INFORMATION:
                         NUMBER              KIND     DATE
                         ---------------------------------
                           WO 2000071135        A1 20001130

DESIGNATED STATES
       W:                AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ
                         DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS
                         JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
                         MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR
                         TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ
```

TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK
ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM
GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-US14505 A 20000525
PRIORITY INFO.: US 1999-60/135,861 19990525
PI WO 2000071135 A1 20001130

DETD . . . rate of division
io and iTi. some cases uncontrolled growth. One examplc o 'i a proliferative cell disorder is a
tumor. In addition to posing a serious health risk in and of themselves, primary malignant
tumors are particularly problematic given their tendency to invade. .
.

In addition to agents of Formula 11, other agents useful in the invention include those
in which the proline residue in Formula 11. . .

In addition, agents can be selected that are effective as anti-proliferative agents or as
anti-angiogenic agents butiare relatively ineffective as hemopoietic cell stimulatory. . .

In addition, agents of Formula I can be selected that are effective as anti-proliferative
agents but are relatively ineffective as hemopoietic cell stimulatory.
. .
. . .
1,3-butane diol. Among the
acceptable vehicles and solvents that may be employed are water, Ringer's solution, and
isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed
as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed
including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid may be
used in the preparation of injectables. Carrier formulations suitable for oral, subcutaneous,
intravenous, intramuscular,. . .
. . .
vehicles include fluid and nutrient replenishers, electrolyte replenishers
(such as those based on Ringer's dextrose), and the like. Preservatives and other additives
may also be present such as, for example, antimicrobials, anti-oxidants, chelating compounds,
and inert gases and the like. The pharmaceutical compositions may. . .
. . .
poly(valeric acid), and poly(lactide-cocaprolactone), and natural polymers such as
alginate and other polysaccharides including dextran and cellulose, collagen, chemical
derivatives thereof (substitutions, additions of chemical groups, for example, alkyl, alkylene,
hydroxylations, oxidations, and other modifications routinely made by those skilled in the
art), albumin and. . .
. . .
active component permeates at a
controlled rate from a polymer such as described in U.S. Patent Nos. 3,854,480, 5,133,974
and 5,407,686. In addition, pump-based hardware delivery systems can be used, some of

which are adapted for implantation.

. . .

levels of IL-6 are secreted from
bone marrow stromal cells of D+ and D- rats. Moreover, IL-6 levels for
both strains were
enhanced by the addition of PT Bone marrow stromal
cells were established from the
long bones of 3 Fischer D+ and D- rats as described. . .

. . .

with the WEHI- 1 64 fibrosarcoma demonstrated that PT- I 00
could suppress the growth of an established s.c. tumor. In
addition, when PT- I 00
administration was started shortly after implantation of VVEHI- 1 64 on
day 2, it was found that
not. . .

CLMEN. . . of first sheet)
This International Searching Authority found multiple inventions in this
internatonal application, as follows:
1 . -1 As all required additional search fees were timely paid
by the applicant, this International Search Report covers all
F searchable claims.

2 As all searchable claims could be searched without effort justifying
an additional fee, this Authority did not invite payment
of any additional fee.

3 As only some of the required additional search fees were
timely paid by the applicant, this International Search Report
F covers only those claims for which fees were. . .

4 F1 No required additional search fees were timely paid by
the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered
by claims Nos.:
Remark on Protest ElThe additional search fees were
accompanied by the applicant's protest.
F-1 No protest accompanied the payment of additional search
fees.
Form PCT/ISA/21 0 1continuation of first sheet (1)) (July 1998)
INTERNATIONAL SEARCH REPORT
International Application No. PCTAis 00 /14505
FURTHER INFORMATION CONTINUED. . .

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.13	3.34

STN INTERNATIONAL LOGOFF AT 16:11:39 ON 19 JUN 2006